Bispecific Antibody Binding To RANKL and Osteonectin with Enhanced Localization to the Bone.
Sign Up to like & getrecommendations! Published in 2017 at "Molecular pharmaceutics"
DOI: 10.1021/acs.molpharmaceut.7b00501
Abstract: Therapeutics reducing bone turnover, such as denosumab (Dmab), an anti-RANKL antibody, can provide treatments for patients with bone destruction. However, some patients with osteoporosis or localized primary bone tumors and many patients with various types… read more here.
Keywords: rankl osteonectin; bone; antibody; bispecific antibody ... See more keywords